Table 2 Demographic and baseline characteristics (intent-to-treat population)
Parameter | Placebo | 25 mg | 50 mg | 100 mg | 200 mg |
|---|---|---|---|---|---|
(n = 77) | (n = 80) | (n = 79) | (n = 80) | (n = 79) | |
Age in years, mean (standard error of the mean) | 62.0 (0.92) | 62.4 (0.86) | 62.6 (0.92) | 62.9 (0.95) | 63.1 (0.80) |
Males, number (percentage) | 23 (30%) | 20 (25%) | 18 (23%) | 23 (29%) | 30 (38%) |
Females, number (percentage) | 54 (70%) | 60 (75%) | 61 (77%) | 57 (71%) | 49 (62%) |
Estrogen/SERM use among females, number (percentage) | |||||
Yes | 5 (9%) | 9 (15%) | 6 (10%) | 5 (9%) | 4 (8%) |
No | 49 (91%) | 51 (85%) | 55 (90%) | 52 (91%) | 45 (92%) |